

SUSPECT ADVERSE REACTION REPORT	
CR-Tolmar-TLM-2025-01849	

I. REACTION INFORMATION

1. PATIENT INITIALS (first, last)	1a. COUNTRY	2. DATE OF BIRTH			2a. AGE Years	3. SEX	4-6 REACTION ONSET			8-12 CHECK ALL APPROPRIATE TO ADVERSE REACTION
VSA	COSTA RICA	Day 04	Month Dec	Year 1931	93	Male	Day	Month	Year 2022	
7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) 1) diagnosed with prostate cancer with bone metastasis/ my grandfather's condition has worsened/ decay in his condition (Progression of prostate cancer (10066489), Prostate cancer (10060862)) Recovering/Resolving 2) Bone metastasis (Metastases to bone (10027452), Metastases to bone (10027452)) (//2022 -) - Not Recovered/Not Resolved/Ongoing 3) Eligard was no longer available in the country (Product supply issue (10077801), Product supply issue (10077801)) Unknown 4) Therefore, patient was switched to Zalodex 10.80 (Product substitution (10076753), Product substitution (10076753)) Unknown <div style="text-align: right;">Cont..</div>										
										<input type="checkbox"/> PATIENT DIED <input type="checkbox"/> LIFE THREATENING <input type="checkbox"/> INVOLVED OR PROLONGED INPATIENT HOSPITALIZATION <input type="checkbox"/> RESULTS IN PERSISTENCE OR SIGNIFICANT DISABILITY/INCAPACITY <input type="checkbox"/> CONGENITAL ANOMALY <input checked="" type="checkbox"/> OTHER MEDICALLY IMPORTANT CONDITION

II. SUSPECT DRUG(S) INFORMATION

14. SUSPECT DRUG(S)(include generic name)		20. DID EVENT ABATE AFTER STOPPING DRUG? <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA
1) Eligard® (Leuprolide acetate, Leuprolide acetate) (Suspect) (Injection)(Unknown) <div style="text-align: right;">Cont..</div>		
15. DAILY DOSE(S)	16. ROUTE(S) OF ADMINISTRATION	
1) (45 milligram(s), 1 in 6 Month)	1) Subcutaneous	21. DID EVENT REAPPEAR AFTER REINTRODUCTION <input type="checkbox"/> YES <input type="checkbox"/> NO <input checked="" type="checkbox"/> NA (NA : Not Applicable)
17. INDICATION(S) FOR USE		
1) Prostate cancer [10060862 - Prostate cancer]		
18. THERAPY DATE(S) (from/to)		19. THERAPY DURATION

III. CONCOMITANT DRUG(S) AND HISTORY

22. CONCOMITANT DRUG(S) AND DATES OF ADMINISTRATION (exclude those used to treat reaction) No concomitants used/reported
23. OTHER RELEVANT HISTORY (e.g. diagnostics, allergies, pregnancy with last month of period, etc.) 1) PROSTATE CANCER (10060862, Prostate cancer) (Continuing: Yes)

IV. MANUFACTURER INFORMATION

24a. NAME AND ADDRESS OF MANUFACTURER Name : Tolmar, Inc 701 Centre Avenue Fort Collins, CO, 80526, UNITED STATES OF AMERICA debbie.maierhofer@tolmar.comand+1-4129158447		Study Information Study Name: NA EudraCT Number: Protocol No.: NA Center No.: Subject Id :
24. REPORT NULLIFIED <input type="checkbox"/> YES <input type="checkbox"/> NO	24b. MFR CONTROL NO. CR-Tolmar-TLM-2025-01849	
24c. DATE RECEIVED BY MANUFACTURER 14/May/2025	24d. REPORT SOURCE <input checked="" type="checkbox"/> STUDY <input type="checkbox"/> LITERATURE <input type="checkbox"/> HEALTH PROFESSIONAL	
DATE OF THIS REPORT 21/May/2025	25a. REPORT TYPE <input checked="" type="checkbox"/> INITIAL <input type="checkbox"/> FOLLOWUP	

= Continuation attached sheet(s)..

Continuation Sheet for CIOMS report

7+13 DESCRIBE REACTION(S) (including relevant tests/lab data) (Continuation...)

5) Eligard was no longer having the expected effect/ lack of efficacy (Lack of drug effect (10023610), Drug ineffective (10013709)(27/Apr/2025 -) - Unknown)

Event Description :

This study report from Brazil was received by Adium Patient Support Program (reference number: CR-ADIUM-CR-0166-20250514) on 14-May-2025 from a consumer (non-healthcare professional) regarding an elderly 93-year old male patient who experienced serious (medically significant) events of "Bone metastasis" (Metastases to bone) and "diagnosed with prostate cancer with bone metastasis/ my grandfather's condition has worsened/ decay in his condition" (Prostate cancer) and non-serious events of "Eligard was no longer having the expected effect" (Drug ineffective), "Eligard was no longer having the expected effect and was no longer available in the country" (Product supply issue), and "Therefore, patient was switched to Zalodex 10.8" (Product substitution) during Eligard (Leuprolide acetate) 45mg therapy for prostate cancer. The needle component of the constituent device was not identified in the report. The report was sent to Tolmar on 15-May-2025.

The patient's medical history was unknown and current condition included prostate cancer.

Concomitant medications were not provided.

On an unknown date, the patient began receiving Eligard of 45 mg strength in 6 months of frequency via subcutaneous route of administration for prostate cancer (Lot numbers and Expiration dates were not provided).

On an unknown date in 2022, the patient had been diagnosed with prostate cancer with bone metastasis for 3 years. He was unaware of his condition, so he was only told that the medication being administered is to keep his prostate healthy and allow him to urinate. In recent months, his condition had worsened, but he was now recovering. According to the latest tests performed, Eligard was no longer having the expected effect and was no longer available in the country.

On 25-Apr-2025, the patient was switched to Zalodex - 10.80 milligram dose - for prostate cancer.

Corrective treatment was not provided.

Action taken with Eligard in response to the events was unknown. De-challenge and re-challenge were not applicable.

The outcome of metastases to bone was not recovered, prostate cancer was recovering and drug ineffective, product substitution and product supply issue was unknown.

The reporter did not assess the seriousness of metastases to bone, prostate cancer, drug ineffective and product substitution and product supply issue.

The reporter assessed the causality of drug ineffective and prostate cancer as related, metastases to bone as not related, product substitution and product supply issue as not reported in relationship to Eligard and Eligard unspecified device

No further queries were raised.

On 19-May-2025, Tolmar case ID QE-027981 was added to the case.

Listedness

Metastases to bone>Eligard® >listed as per CCDS Eligard®> 7-Nov-2024
Metastases to bone> Eligard® >listed as per Canadian Monograph Eligard®> 2-Apr-2025
Metastases to bone> Eligard®>listed as per USPI Eligard®>Feb-2025
Metastases to bone> Eligard® Unspecified Device> listed as per USPI Eligard®>Feb-2025

Prostate cancer>Eligard® >listed as per CCDS Eligard®> 7-Nov-2024
Prostate cancer> Eligard® >listed as per Canadian Monograph Eligard®> 2-Apr-2025
Prostate cancer> Eligard®>listed as per USPI Eligard®>Feb-2025
Prostate cancer> Eligard® Unspecified Device> listed as per USPI Eligard®>Feb-2025

Product supply issue >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Product supply issue > Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Product supply issue > Eligard®>unlisted as per USPI Eligard®>Feb-2025
Product supply issue > Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Product substitution >Eligard® >unlisted as per CCDS Eligard®> 7-Nov-2024
Product substitution> Eligard® >unlisted as per Canadian Monograph Eligard®> 2-Apr-2025
Product substitution> Eligard®>unlisted as per USPI Eligard®>Feb-2025
Product substitution> Eligard® Unspecified Device>unlisted as per USPI Eligard®>Feb-2025

Continuation Sheet for CIOMS report

Drug ineffective >Eligard® >listed as per CCDS Eligard®> 7-Nov-2024
 Drug ineffective> Eligard® >listed as per Canadian Monograph Eligard®> 2-Apr-2025
 Drug ineffective> Eligard®>listed as per USPI Eligard®>Feb-2025
 Drug ineffective> Eligard® Unspecified Device>listed as per USPI Eligard®>Feb-2025

Company Remarks (Sender's Comments) :

Evaluator comment (Tolmar): The case is regarding an elderly 93-year old male patient who reported events of Metastases to bone (Bone metastasis), Prostate cancer(diagnosed with prostate cancer with bone metastasis/ my grandfather's condition has worsened/ decay in his condition), Drug ineffective (Eligard was no longer having the expected effect), Product supply issue (Eligard was no longer having the expected effect and was no longer available in the country), Product substitution (Therefore, patient was switched to Zalodex 10.8) during Eligard (Leuprolide acetate) 45mg therapy for prostate cancer. Tolmar assessed the events bone metastasis and prostate cancer as serious (medically significant) as these events are included in IME list and rest of the events were assessed as non-serious since they did not meet the ICH seriousness criteria. The causality of the events bone metastasis and prostate cancer were assessed as not related to suspect Eligard(Drug and device) as these events could be attributed to underlying prostate cancer which is known to progress despite treatment. The causality of event drug ineffective was assessed as related to suspect drug Eligard (not related to device) based on timeline association with Eligard administration and given that the effect of drug may vary from person to person. The causality of events product substitution due to product supply issue was assessed as not related to suspect Eligard(drug and device) as it was human action due circumstances.

14.SUSPECT DRUG(S) (Continuation...)

Product-Reaction Level

1) Drug : Eligard® (Leuprolide acetate)
 Active Substance : 1) Leuprolide acetate
 Drug Characterization : Suspect
 Form of Admin : 1) Injection
 Lot Number : 1) Unknown
 Daily Dose : (45 milligram(s), 1 in 6 Month)
 Route of Admin : 1) Subcutaneous
 Indications : 1) Prostate cancer [10060862 - Prostate cancer]
 Action(s) Taken With Drug : Unknown

Causality

1) diagnosed with prostate cancer with bone metastasis/ my grandfather's condition has worsened/ decay in his condition (Progression of prostate cancer - 10066489, Prostate cancer - 10060862)

Causality as per reporter : Related
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

2) Bone metastasis (Metastases to bone - 10027452, Metastases to bone - 10027452)

Causality as per reporter : Not Related
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

3) Eligard was no longer available in the country (Product supply issue - 10077801, Product supply issue - 10077801)

Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

4) Therefore, patient was switched to Zalodex 10.80 (Product substitution - 10076753, Product substitution - 10076753)

Causality as per reporter : Not Reported
 Causality as per Mfr : Not Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

5) Eligard was no longer having the expected effect/ lack of efficacy (Lack of drug effect - 10023610, Drug ineffective - 10013709)

Causality as per reporter : Related
 Causality as per Mfr : Related
 DeChallenge : Not applicable
 ReChallenge : Not Applicable

Labeling :

1) diagnosed with prostate cancer with bone metastasis/ my grandfather's condition has worsened/ decay in his condition
 CORE Labeled
 2) Bone metastasis
 CORE Labeled

Continuation Sheet for CIOMS report

- 3) Eligard was no longer available in the country
CORE UnLabeled
- 4) Therefore, patient was switched to Zalodex 10.80
CORE UnLabeled
- 5) Eligard was no longer having the expected effect/ lack of efficacy
CORE Labeled
- 2) Drug : Eligard® Unspecified Device (Leuprolide acetate)
Active Substance : 1) Leuprolide acetate
Drug Characterization : Suspect
Form of Admin : 1) Injection
Lot Number : 1) Unknown
Indications : 1) Prostate cancer [10060862 - Prostate cancer]
Action(s) Taken With Drug : Not applicable

Causality

- 1) diagnosed with prostate cancer with bone metastasis/ my grandfather's condition has worsened/ decay in his condition (Progression of prostate cancer - 10066489, Prostate cancer - 10060862)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
- 2) Bone metastasis (Metastases to bone - 10027452, Metastases to bone - 10027452)
Causality as per reporter : Not Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
- 3) Eligard was no longer available in the country (Product supply issue - 10077801, Product supply issue - 10077801)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
- 4) Therefore, patient was switched to Zalodex 10.80 (Product substitution - 10076753, Product substitution - 10076753)
Causality as per reporter : Not Reported
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable
- 5) Eligard was no longer having the expected effect/ lack of efficacy (Lack of drug effect - 10023610, Drug ineffective - 10013709)
Causality as per reporter : Related
Causality as per Mfr : Not Related
DeChallenge : Not applicable
ReChallenge : Not Applicable

Labeling :

- 1) diagnosed with prostate cancer with bone metastasis/ my grandfather's condition has worsened/ decay in his condition
CORE
- 2) Bone metastasis
CORE
- 3) Eligard was no longer available in the country
CORE
- 4) Therefore, patient was switched to Zalodex 10.80
CORE
- 5) Eligard was no longer having the expected effect/ lack of efficacy
CORE